CA3153921A1 - External preparation for treating epilepsy or autism spectrum disorder - Google Patents

External preparation for treating epilepsy or autism spectrum disorder Download PDF

Info

Publication number
CA3153921A1
CA3153921A1 CA3153921A CA3153921A CA3153921A1 CA 3153921 A1 CA3153921 A1 CA 3153921A1 CA 3153921 A CA3153921 A CA 3153921A CA 3153921 A CA3153921 A CA 3153921A CA 3153921 A1 CA3153921 A1 CA 3153921A1
Authority
CA
Canada
Prior art keywords
sirolimus
topical preparation
gel
day
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3153921A
Other languages
English (en)
French (fr)
Inventor
Mari KANEDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3153921A1 publication Critical patent/CA3153921A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3153921A 2019-10-16 2020-10-07 External preparation for treating epilepsy or autism spectrum disorder Pending CA3153921A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-189091 2019-10-16
JP2019189091 2019-10-16
PCT/JP2020/037986 WO2021075328A1 (ja) 2019-10-16 2020-10-07 てんかん治療用又は自閉症スペクトラム障害治療用外用剤

Publications (1)

Publication Number Publication Date
CA3153921A1 true CA3153921A1 (en) 2021-04-22

Family

ID=75537453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3153921A Pending CA3153921A1 (en) 2019-10-16 2020-10-07 External preparation for treating epilepsy or autism spectrum disorder

Country Status (7)

Country Link
US (1) US20240058365A1 (https=)
EP (1) EP4046637A4 (https=)
JP (1) JP7601398B2 (https=)
CN (1) CN114555081A (https=)
AU (1) AU2020365665A1 (https=)
CA (1) CA3153921A1 (https=)
WO (1) WO2021075328A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526889A (ja) * 2008-06-30 2011-10-20 アフギン ファーマ,エルエルシー 局所局部的神経作用療法
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
CA2825786A1 (en) * 2011-01-31 2012-08-09 Osaka University Externally-used drug for treating skin disorder and method for producing same
CN104490873A (zh) * 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
JP6541124B2 (ja) * 2015-03-23 2019-07-10 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases

Also Published As

Publication number Publication date
AU2020365665A1 (en) 2022-04-14
WO2021075328A1 (ja) 2021-04-22
CN114555081A (zh) 2022-05-27
JPWO2021075328A1 (https=) 2021-04-22
JP7601398B2 (ja) 2024-12-17
EP4046637A4 (en) 2023-11-01
US20240058365A1 (en) 2024-02-22
EP4046637A1 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
KR101267901B1 (ko) 프로스타글란딘 e₁을 포함하는 에멀션 조성물
EP2120860B1 (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
CA2728727C (en) Pharmaceutical transdermal compositions and method for treating inflammation in cattle
JP2016130224A (ja) 外用組成物
KR101817028B1 (ko) 지속성 케토프로펜 조성물
KR101894521B1 (ko) 흉터치료를 위한 국소용 약학적 조성물
JP6541124B2 (ja) びまん性神経線維腫用の外用薬
US20240058365A1 (en) External Preparation for Treating Epilepsy or Autism Spectrum Disorder
JP2011102260A (ja) タクロリムス外用剤
KR101018819B1 (ko) 티오우레아 유도체를 함유하는 소양성 또는 자극성피부질환의 예방 또는 치료용 외용제 조성물
HUT74448A (en) Process for preparing pharmaceutical compns. contg. ibuprofen and flurbiprofen for use as anti-pruritic agents
JP7446711B2 (ja) 皮膚外用組成物
HK40065801A (zh) 用於治疗癫痫或用於治疗自闭症谱系障碍的外用剂
EP3932487A1 (en) External preparation for vascular abnormality treatment
JP7514598B2 (ja) 皮膚外用組成物
WO2019002367A1 (en) TOPICAL COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
JP2003534277A (ja) 生存性改善
EP3305312A1 (en) External preparation for transdermal administration
CN117462483A (zh) 加巴喷丁在制备用于治疗宠物瘙痒的乳膏制剂中的用途
KR20230064809A (ko) 마그놀린을 유효성분으로 포함하는 신경병성 통증 치료용 조성물

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241028

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241028

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250404

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250714

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251118